Cartesian Therapeutics

Nasdaq RNAC · Frederick, MD

Works in Cardiovascular · Dermatology · Hematology · Immunology · Infectious disease · Musculoskeletal · Neurology · Oncology · Respiratory

Cartesian Therapeutics is a clinical trial sponsor based in Frederick, MD, listed as Nasdaq RNAC. It has 5 active clinical trials with 274 planned participants, across 9 therapeutic areas. Since 2021 it has completed 1 trial and stopped 6 early.

Trial track record · since 2021

5Active trials274 planned participants
1Completed4 with results posted
6Stopped early86% of finished trials

Financials · Nasdaq RNAC

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 5 active trials

StageTrialStatus

Questions about Cartesian Therapeutics

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-01.

Approve Suite is not affiliated with Cartesian Therapeutics. Informational only.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.